Earlier today, we reported our fourth quarter and full-year financial results, which were ahead of our previously communicated guidance. We finished the year strong, delivering full year organic sales growth of 2%, operating EBITDA growth of 6%, and 100 basis points of margin expansion. Operational discipline and a focus on productivity were key to our earnings growth and margin improvement. These results led to an adjusted EPS of $1.68 per share, up 16% year-over-year.

We set the strategic direction of new DuPont, starting with enhancing our core values to drive a culture focused on growth and continuous improvement. We have successfully repositioned ourselves and have a streamlined portfolio of leading businesses, the majority of which are aligned to secular end markets, which will enable strong organic growth. We saw 2% organic growth for full year 2025 and expect that to accelerate to about 3% in 2026. We are well-positioned in secular end markets, and our top-line growth will continue to be bolstered by our innovation engine, which launched more than 125 new products in 2025.

We have completed a maturity assessment resulting in the identification of key initiatives in 2026 centered primarily on demand generation and pipeline discipline. On capital allocation, we have a proven model that enables both consistent investments and high-return organic opportunities, as well as bolting on to existing businesses with M&A to enable even greater returns. We will continue to return cash to shareholders through a quarterly dividend in line with our targeted payout ratio, as well as utilizing share repurchases. With these priorities, let's move to our 2026 outlook on slide 5.

What went well
  • Full year 2025 delivered organic sales growth of 2%, operating EBITDA growth of 6%, 100 basis points of margin expansion, and adjusted EPS of $1.68, up 16% year-over-year.
  • Fourth quarter operating EBITDA of $409 million increased 4% on favorable mix and cost productivity, with operating EBITDA margin of 24.2%, up 80 basis points year-over-year.
  • Fourth quarter adjusted EPS of $0.46 was up 18% versus the year-ago period.
  • Healthcare & Water Technologies grew 3% organically in Q4 (5% adjusting for the order timing shift), led by continued strength in medical packaging and medical devices.
  • Completed the separation of Qnity Electronics, standing up a pure-play semiconductor technology solutions partner, and executed a $500 million ASR in Q4 under the $2 billion authorization.
  • Launched more than 125 new products in 2025 generating greater than $2 billion in sales, with a Vitality Index of about 30% and about 145 basis points of margin lift from products introduced in the past five years.
What went wrong
  • Fourth quarter net sales of $1.7 billion were about flat, with a 1% organic sales decline including a $30 million (2%) headwind from order timing shifts into Q3 due to system cutover activities ahead of the electronics separation.
  • Diversified Industrials net sales fell 3% in Q4 on a 4% organic decline (down 2% adjusting for the order timing shift).
  • Building Technologies organic sales were down high single digits on continued weakness in construction markets.
  • Industrial Technologies organic sales were down low single digits as strength in aerospace was more than offset by weakness in printing and packaging markets.
  • Asia-Pacific organic sales were down 2% year-over-year, primarily due to a supply chain change in the Shelter business (a distributor joint venture relationship change).

Guidance Changes

MetricPeriodCurrent guidance

Performance Breakdown

MetricYoYNote

Earnings Call Themes & Trends

TopicPrevious mentionCurrent periodTrend

Q&A Summary

More on DuPont de Nemours, Inc.

Reported 2026-02-10 · figures from the DuPont de Nemours, Inc. Q4 2025 earnings call.

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

You're subscribed.

Thanks for signing up.